Literature DB >> 29057308

RAS oncogenes direct metastasis.

Magda Spella1, Antonia Marazioti1, Kristina A M Arendt2, Georgios T Stathopoulos1,2.   

Abstract

RAS genes are cardinal driver oncogenes frequently and differentially mutated across bodily tumors. Their tumorigenic potential has been mainly ascribed to autonomous promotion of tumor cell proliferation and survival. However, recent evidence shows that RAS oncogenes also function to define metastatic tropism. Interestingly, RAS-driven metastasis is mediated by distinct chemokine sets that signal to endothelial and myeloid cells.

Entities:  

Keywords:  Chemokines; KRAS; Lung metastasis; Malignant pleural effusion; NRAS

Year:  2017        PMID： 29057308      PMCID： PMC5644486          DOI： 10.1080/23723556.2017.1345711

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

1.  A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival.

Authors:  Anurag Singh; Patricia Greninger; Daniel Rhodes; Louise Koopman; Sheila Violette; Nabeel Bardeesy; Jeff Settleman
Journal:  Cancer Cell       Date:  2009-06-02       Impact factor: 31.743

2.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.

Authors:  Ramin Nazarian; Hubing Shi; Qi Wang; Xiangju Kong; Richard C Koya; Hane Lee; Zugen Chen; Mi-Kyung Lee; Narsis Attar; Hooman Sazegar; Thinle Chodon; Stanley F Nelson; Grant McArthur; Jeffrey A Sosman; Antoni Ribas; Roger S Lo
Journal:  Nature       Date:  2010-11-24       Impact factor: 49.962

3.  Rare codons regulate KRas oncogenesis.

Authors:  Benjamin L Lampson; Nicole L K Pershing; Joseph A Prinz; Joshua R Lacsina; William F Marzluff; Christopher V Nicchitta; David M MacAlpine; Christopher M Counter
Journal:  Curr Biol       Date:  2012-12-13       Impact factor: 10.834

Review 4.  Dragging ras back in the ring.

Authors:  Andrew G Stephen; Dominic Esposito; Rachel K Bagni; Frank McCormick
Journal:  Cancer Cell       Date:  2014-03-17       Impact factor: 31.743

Review 5.  A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer.

Authors:  Neil Vasan; Julie L Boyer; Roy S Herbst
Journal:  Clin Cancer Res       Date:  2014-06-03       Impact factor: 12.531

6.  Kras regulatory elements and exon 4A determine mutation specificity in lung cancer.

Authors:  Minh D To; Christine E Wong; Anthony N Karnezis; Reyno Del Rosario; Roberto Di Lauro; Allan Balmain
Journal:  Nat Genet       Date:  2008-08-31       Impact factor: 38.330

7.  Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis.

Authors:  Anke Sparmann; Dafna Bar-Sagi
Journal:  Cancer Cell       Date:  2004-11       Impact factor: 31.743

8.  NRAS destines tumor cells to the lungs.

Authors:  Anastasios D Giannou; Antonia Marazioti; Nikolaos I Kanellakis; Ioanna Giopanou; Ioannis Lilis; Dimitra E Zazara; Giannoula Ntaliarda; Danai Kati; Vasileios Armenis; Georgia A Giotopoulou; Anthi C Krontira; Marina Lianou; Theodora Agalioti; Malamati Vreka; Maria Papageorgopoulou; Sotirios Fouzas; Dimitrios Kardamakis; Ioannis Psallidas; Magda Spella; Georgios T Stathopoulos
Journal:  EMBO Mol Med       Date:  2017-05       Impact factor: 12.137

9.  Mutant KRAS promotes malignant pleural effusion formation.

Authors:  Theodora Agalioti; Anastasios D Giannou; Anthi C Krontira; Nikolaos I Kanellakis; Danai Kati; Malamati Vreka; Mario Pepe; Magda Spella; Ioannis Lilis; Dimitra E Zazara; Eirini Nikolouli; Nikolitsa Spiropoulou; Andreas Papadakis; Konstantina Papadia; Apostolos Voulgaridis; Vaggelis Harokopos; Panagiota Stamou; Silke Meiners; Oliver Eickelberg; Linda A Snyder; Sophia G Antimisiaris; Dimitrios Kardamakis; Ioannis Psallidas; Antonia Marazioti; Georgios T Stathopoulos
Journal:  Nat Commun       Date:  2017-05-16       Impact factor: 14.919

10.  Specific KRAS amino acid substitutions and EGFR mutations predict site-specific recurrence and metastasis following non-small-cell lung cancer surgery.

Authors:  Stéphane Renaud; Joseph Seitlinger; Pierre-Emmanuel Falcoz; Mickaël Schaeffer; Anne-Claire Voegeli; Michèle Legrain; Michèle Beau-Faller; Gilbert Massard
Journal:  Br J Cancer       Date:  2016-06-23       Impact factor: 7.640
  10 in total
  1 in total

1.  Antimetastatic effect of epigenetic drugs, hydralazine and valproic acid, in Ras-transformed NIH 3T3 cells.

Authors:  Enrique Pérez-Cárdenas; Lucía Taja-Chayeb; Catalina Trejo-Becerril; José Chanona-Vilchis; Alma Chávez-Blanco; Guadalupe Domínguez-Gómez; Elizabeth Langley; Alejandro García-Carrancá; Alfonso Dueñas-González
Journal:  Onco Targets Ther       Date:  2018-12-07       Impact factor: 4.345
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.